Clinical Trial

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Study acronym: MAHOGANY
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Protocol Amendment History 4 changes
notable Trial sites expanded: 257 -> 270 locations 2026-07-24
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-16
notable Trial sites reduced: 277 -> 257 locations 2026-07-16
notable Sponsor changed: BeiGene -> BeOne Medicines 2026-06-11
Trial Details
NCT Number NCT05100862
Lead Sponsor BeOne Medicines
Conditions Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Enrollment 799 participants
Start Date 2022-03-10
Primary Completion 2028-07 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-06